DRL-Header DRL-Header

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Neurology Drugs in Phase I Clinical Development in SWITZERLAND

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshReset Filter
              refresh Reset Filter
              price-trend All Drugs in Dev.

              Product Type

              Companies

              Anokion SA

              • Development Update

              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content
              Digital Content Digital Content

              CPhI Middle East & Africa 2021

              Participation Not Confirmed

              Update your events

              Anokion Initiates Patient Dosing in Phase 1 Trial of ANK-700 for the Treatment of Mul...

              Lead Product(s): ANK-700

              Therapeutic Area: Neurology Product Name: ANK-700

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 23, 2021

              Details:

              The MoveS-it Study (Multiple Sclerosis Study of ANK-700 to Assess Safety and Immune Tolerance) is a randomized, double-blind, placebo-controlled, first-in-human study designed to evaluate the safety and tolerability of single and multiple ascending doses of ANK-700.